Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Gastrointestinal Stromal Tumor Sarcoma

Completed

1

Start Date 12/01/2004

Age of Trial (yrs) 20.4

Gleevec-resistant

Transcription inhibitor + Chemotherapy

Freeze the cell division cycle

Specifically GIST plus other cancers

CDR0000398181, MSKCC-04075, NCI-6204

Memorial Sloan-Kettering NCI

See site contact info below

no

IV Intravenous

This is a phase I trial to determine the maximum tolerated dose of the combination of doxorubicin (a traditional cytotoxic chemotherapy) with flavopiridol (an inhibitor of the cell cycle and an inhibitor of transcription). This trial is for sarcoma patients, including GIST patients, that are 18 years old or older. Patients must have a Performance status of ECOG 0-2 or Karnofsky 60-100%. Projected accrual is 3 to 36 patients.

The trial is being conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, N.Y. U.S.A. The principal investigator is Dr. David D’Adamo.